Compare Adobe Systems Inc (ADBE) vs Novartis AG (NVS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adobe Systems Inc vs Novartis AG — how do they compare? Adobe Systems Inc trades at $220.66 (market cap $88.06B), while Novartis AG trades at $155.47 (market cap $298.98B). The key difference: Novartis AG is far larger — about 3.4× Adobe Systems Inc's market cap, and Novartis AG pays a 3.02% dividend while Adobe Systems Inc pays none. Which is the better fit depends on your goals.
| ADBE | NVS | |
|---|---|---|
Market Cap | $88.06B | $298.98B |
Volume | 5,187,646 | — |
Sector | Technology | Health |
52-Week High | $382.24 | $168.62 |
52-Week Low | $193.41 | $113.50 |
Enterprise Value | $89.50B | $339.00B |
Dividend Yield | — | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adobe (ADBE) trades at $219.75, up 0.77% with strong fundamentals including 29.99% net margin and consistent earnings beats. The stock shows bullish technical signals despite recent volatility, with support at $218 and resistance at $228. Revenue growth accelerated to $23.77B in 2025, while institutional activity remains mixed amid AI competition concerns.
ADBE presents a compelling value opportunity with a 12.67 P/E ratio and 49% analyst buy ratings, though AI disruption fears and CEO transition create near-term uncertainty. The consensus price target of $246.75 implies 12% upside potential, balanced against sector-wide software pressures.
Novartis (NVS) trades at $157.03, down 1.79% with mixed technical signals showing bullish moving averages but neutral oscillators. The company demonstrates strong fundamentals with $56.67B revenue, 23.92% net margin, and robust cash flow generation. Recent developments include multiple strategic acquisitions and regulatory approvals expanding the oncology pipeline, though earnings have shown volatility with two misses in the last four quarters.
NVS presents a balanced investment case with strong profitability and pipeline expansion offset by valuation concerns and earnings inconsistency. The stock offers stability through defensive healthcare exposure but faces execution risks from integration challenges and competitive pressures in pharmaceutical markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adobe Systems Inc
Adobe Inc. develops, markets, and supports computer software products and technologies. The Company's products allow users to express and use information across all print and electronic media. Adobe offers a line of application software products, type products, and content for creating, distributing, and managing information.
Read more on ADBE →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
